Lilly Asia & AstraZeneca-CICC Fund in AI-biomedicine Platform
21 Nov 2024
US$ 19.00
Lilly Asia Ventures and CICC Capital Management, through its AstraZeneca-CICC Healthcare Industrial Fund, were party ......
Related Publications
Subscribers’ Weekly ending 22 Nov 2024...
Listen to Australia/New Zealand Investments (Subscribers' Weekly 22 Nov 2024)...
Connect With Us
We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.
Rest assured that your email address will not be shared, as we hate spams as much as you do.